Ucb S.A. · EURONEXT:UCB

Ucb — FY2017 Earnings Presentation

53 slides from Ucb's earnings presentation, Feb 22, 2018

  1. Slide 1: 2017 full year financial report

    Slide 1: 2017 full year financial report

    UCB Inspired by patients. Driven by science. 2017 full year financial report Brussels, 22 February 2018

  2. Slide 2: Disclaimer and safe harbor

    Slide 2: Disclaimer and safe harbor

    2017 FY results 2 Disclaimer and safe harbor Forward-looking statements This presentation contains forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, and “continue”

  3. Slide 3: UCB FY 2017 information flow

    Slide 3: UCB FY 2017 information flow

    2017 FY results 3 UCB FY 2017 information flow ‫ ן‬A strong year 2017, reinforcing a solid foundation for investing in future growth • Jean-Christophe Tellier, CEO ‫ ן‬Increasing value of UCB's early and late-stage pipeline • Dhavalkumar Patel, CSO ‫ ן‬Bimekizumab Phase 2b: 3 x positive results • Do

  4. Slide 4: Driving value for patients

    Slide 4: Driving value for patients

    2017 FY results 4 Driving value for patients Examples for 2017 achievements From Solution to Patient From Patient to Science • Innovative extrapolation - faster access • Cimzia® for women of childbearing age for patients • UCB0107 – Tau antibody Briviact® monotherapy, Vimpat® pediatric epilepsy • Al

  5. Slide 5: UCB is progressing on our strategic growth path

    Slide 5: UCB is progressing on our strategic growth path

    2017 FY results 5 UCB is progressing on our strategic growth path 2017 achievements – delivering on our commitments Grow core products Cimzia®, Vimpat®, Keppra®, Briviact® + Neupro® combined net sales: € 3.6 billion (+13%) Advance and prepare launch of next wave bimekizumab with strong positive & co

  6. Slide 6: Increasing value of UCB's early and late-stage pipeline

    Slide 6: Increasing value of UCB's early and late-stage pipeline

    6 Increasing value of UCB's early and late-stage pipeline Dhavalkumar Patel, MD, PhD CSO

  7. Slide 7: Increasing value of UCB's early and late-stage pipeline

    Slide 7: Increasing value of UCB's early and late-stage pipeline

    2017 FY results 7 Increasing value of UCB's early and late-stage pipeline Driven by strong UCB science and technology platforms Phase 1 Phase 2 radiprodil Phase 3 UCB0599 Filing padsevonil seletalisib epilepsy UCB0107 UCB4144 bimekizumab psoriasis, psoriatic arthritis romosozumab dapirolizumab pegol

  8. Slide 8: We keep strengthening our leadership in epilepsy with padsevonil

    Slide 8: We keep strengthening our leadership in epilepsy with padsevonil

    2017 FY results 8 We keep strengthening our leadership in epilepsy with padsevonil Key facts Key insight Padsevonil’s unique impact… … is driven by a unique dual mechanism • ~30% of epilepsy patients are drug-resistant and Pre- & Post-Synaptic Inhibition (PPSI) lack treatment options • Padsevonil sh

  9. Slide 9: UCB0107, an anti-Tau antibody for PSP & Alzheimer's disease

    Slide 9: UCB0107, an anti-Tau antibody for PSP & Alzheimer's disease

    2017 FY results 9 UCB0107, an anti-Tau antibody for Progressive Supranuclear Palsy & Alzheimer’s disease Key facts Key insights UCB0107 blocks tau uptake and aggregation UCB0107 was generated Tau seeds spread to block spreading of tau from dying cells to • PSP is a rare, rapidly progressing seeds fr

  10. Slide 10: Rozanolixizumab, a first-in-class SubQ treatment for IgG-mediated diseases

    Slide 10: Rozanolixizumab, a first-in-class SubQ treatment for IgG-mediated diseases

    2017 FY results 10 Rozanolixizumab, a first-in-class SubQ treatment for IgG-mediated diseases like ITP & Myasthenia Gravis Key facts Key data Rozanolixizumab is set to replace Data indicate dose-dependent standard IVIg and PEX therapies lowering of IgG serum levels in healthy volunteers Relative cha

  11. Slide 11: Our antibody technology platform is a core value driver

    Slide 11: Our antibody technology platform is a core value driver

    2017 FY results 11 Our antibody technology platform is a core value driver of our pipeline Key facts Key example UCB0159 is our first bispecific antibody Strong antibody platform in the clinic, more to follow • Highly automated and efficient • UCB0159 has good potency for multiple cytokines discover

  12. Slide 12: Bimekizumab Phase 2b: 3 x positive results

    Slide 12: Bimekizumab Phase 2b: 3 x positive results

    12 Bimekizumab Phase 2b: 3 x positive results Dominique Baeten, MD, PhD Professor of Rheumatology Head of the New Patient Value Mission

  13. Slide 13: Translating scientific hypotheses into clinical differentiation

    Slide 13: Translating scientific hypotheses into clinical differentiation

    2017 FY results 13 Translating scientific hypotheses into clinical differentiation Dual blockade of IL-17F and IL-17A by bimekizumab IL-17A IL-17F IL-17RC IL-17RA IL-17F and IL-17A are Dual blockade of Bimekizumab specifically and twin cytokines IL-17F on top of IL-17A completely blocks driving join

  14. Slide 14: Bimekizumab proof of concept

    Slide 14: Bimekizumab proof of concept

    2017 FY results 14 Translating scientific hypotheses into clinical differentiation Bimekizumab proof of concept Migration of neutrophils ACR50 - Joint PASI90 - Skin (G) 700000 93% 87% 600000 500000 57% Neutrophil number 400000 300000 40% PASI 90 (%) ACR50 (%) 200000 55% 15% 100000 7% 1% 1% 0 Week 8

  15. Slide 15: Bimekizumab current development program

    Slide 15: Bimekizumab current development program

    2017 FY results 15 Bimekizumab current development program First monoclonal antibody neutralizing IL-17F on top of IL-17A Psoriatic arthritis Ankylosing spondylitis Psoriasis (NCT02969525) (NCT02963506) (NCT02905006) • 206 patients living with • 303 patients living with • 250 patients living with ac

  16. Slide 16: Bimekizumab: Strong positive results from BE ACTIVE

    Slide 16: Bimekizumab: Strong positive results from BE ACTIVE

    2017 FY results 16 Bimekizumab: Strong positive results from BE ACTIVE Significantly improve joint and skin symptoms in phase 2b 206 patients living with active psoriatic arthritis: Up to 46% achieved ACR501 with bimekizumab vs. 7% placebo bimekizumab placebo 12 weeks 12 weeks ACR50: patients experi

  17. Slide 17: Bimekizumab: Strong positive results from BE ACTIVE

    Slide 17: Bimekizumab: Strong positive results from BE ACTIVE

    2017 FY results 17 Bimekizumab: Strong positive results from BE ACTIVE Significantly improve joint and skin symptoms in phase 2b … and up to 65% of patients with bimekizumab achieved at least 90% skin clearance (PASI90) vs. 7% placebo bimekizumab placebo 12 weeks 12 weeks PASI90: patients experienci

  18. Slide 18: Bimekizumab: Strong positive results from BE AGILE

    Slide 18: Bimekizumab: Strong positive results from BE AGILE

    2017 FY results 18 Bimekizumab: Strong positive results from BE AGILE Significant improvement in multiple dose groups in phase 2b 303 patients living with active ankylosing spondylitis: Up to 47% achieved ASAS401 with bimekizumab vs. 13% placebo bimekizumab placebo 12 weeks 12 weeks ASAS40: at least

  19. Slide 19: Bimekizumab: Strong positive results from BE ABLE

    Slide 19: Bimekizumab: Strong positive results from BE ABLE

    2017 FY results 19 Bimekizumab: Strong positive results from BE ABLE Significantly improve skin symptoms in phase 2b 250 patients living with moderate to severe chronic plaque psoriasis1: Up to 79% achieved at least 90% skin clearance (PASI90) with bimekizumab vs. 0% placebo bimekizumab placebo 12 w

  20. Slide 20: Bimekizumab: Strong positive results from BE ABLE

    Slide 20: Bimekizumab: Strong positive results from BE ABLE

    2017 FY results 20 Bimekizumab: Strong positive results from BE ABLE Significantly improve skin symptoms in phase 2b 250 patients living with moderate to severe chronic plaque psoriasis1: Up to 60% achieved complete skin clearance (PASI100) with bimekizumab vs. 0% placebo bimekizumab placebo 12 week

  21. Slide 21: Next: Phase 3 programs for clinical differentiation

    Slide 21: Next: Phase 3 programs for clinical differentiation

    2017 FY results 21 Next: Phase 3 programs for clinical differentiation Robust Phase 2b studies in 3 related indications • All 3 studies met primary and secondary endpoints • Rapid and profound clinical efficacy on relevant endpoints • Both for joints and for skin • Consistent across the three 12-wee

  22. Slide 22: Continued above market growth in 2017

    Slide 22: Continued above market growth in 2017

    22 Continued above market growth in 2017 Detlef Thielgen, CFO

  23. Slide 23: UCB FY 2017 financial highlights

    Slide 23: UCB FY 2017 financial highlights

    2017 FY results 23 UCB FY 2017 financial highlights Core product growth drive top and bottom line Actual CER Revenue € 4 530 million +9% +11% • Net sales up by 9% (+11% CER) to € 4.2 billion driven by core products (€ 3.6 billion; +13%) Total operating expenses € 2 200 million +2% +4% • Overall oper

  24. Slide 24: Strong net sales growth from core products

    Slide 24: Strong net sales growth from core products

    2017 FY results 24 Strong net sales growth from core products Generating € 3.6 billion (+13%) Cimzia® € 1.42 bn +9% (+11% CER) • Sustainable performance Vimpat® € 0.98 bn +19% (+21% CER) • Strong, sustainable growth in all markets Keppra® € 0.78 bn +8% (+11% CER) • Strong growth in international mar

  25. Slide 25: 30% rEBITDA target for 2018 - already reached in 2017

    Slide 25: 30% rEBITDA target for 2018 - already reached in 2017

    2017 FY results 25 30% rEBITDA target for 2018 - already reached in 2017 Top line growth, efficient resources allocation and tight cost control lead to improved ratios* Gross margin / revenue Operating expense / revenue Recurring EBITDA / revenue 30% target for 2018 30.3% 74% 70% 71% 24.9% 69% 69% 6

  26. Slide 26: Solid, sustainable top and bottom line growth

    Slide 26: Solid, sustainable top and bottom line growth

    2017 FY results 26 Solid, sustainable top and bottom line growth Strong foundation enabling future growth and investment in innovation Revenue Recurring EBITDA 4.53 1.38 4.15 3.88 3.34 1.03 3.14 0.82 0.61 0.54 € billion € billion 2013 2014 2015 2016 2017 2013 2014 2015 2016 2017

  27. Slide 27: 2017 financial targets achieved

    Slide 27: 2017 financial targets achieved

    2017 FY results 27 2017 financial targets achieved 30.3 % rEBITDA margin – one year ahead of guidance 2017 financial targets vs. Mid-term financial targets vs. 2017 achievements 2017 achievements Revenue € 4.4 - 4.5 billion Net debt / rEBITDA = 1:1 by 2018 € 4.53 billion (+9%) 0.8 in 2016; 0.4 in 20

  28. Slide 28: 2018 financial outlook and new midterm guidance

    Slide 28: 2018 financial outlook and new midterm guidance

    2017 FY results 28 2018 financial outlook and new midterm guidance Maximize (new) growth drivers and strengthen sustainability 2018 financial targets Guidance target 2021 and beyond Revenue € 4.5 - 4.6 billion rEBITDA / revenue ratio of 31% in 2021 • Continued strong core product growth • One-time e

  29. Slide 29: UCB's Patient Value Strategy

    Slide 29: UCB's Patient Value Strategy

    2017 FY results 29 UCB's Patient Value Strategy Our ambition is to be the patient preferred biotech leader, creating patient value for specific populations through unique outcomes, the best experience and improving as many of these lives as possible. This will lead to sustainable growth Mariana, for

  30. Slide 30: Your Questions, please

    Slide 30: Your Questions, please

    2017 FY results 30 Your Questions, please UCB's strategic growth path True differentiation drives leadership and sustainability Breakthrough phase Growth expansion Strong growth

  31. Slide 31: Further facts and figures

    Slide 31: Further facts and figures

    Further facts and figures Fa Inspired by patients. kd Driven by science.

  32. Slide 32: Recurring EBITDA

    Slide 32: Recurring EBITDA

    2017 FY results 32 Recurring EBITDA Solid growth - Improved operating expenses ratio Restated after reclassification due to IFRS 15 EBIT: Earnings before interest and taxes CER: constant exchange rate EBITDA: Earning before interests, taxes, depreciation and amortization charges

  33. Slide 33: 2017 profit

    Slide 33: 2017 profit

    2017 FY results 33 2017 profit CER: constant exchange rate EBIT: Earnings before interest and taxes

  34. Slide 34: Core earnings per share

    Slide 34: Core earnings per share

    2017 FY results 34 Core earnings per share Strong growth of core net profit

  35. Slide 35: 2017 key product net sales performance

    Slide 35: 2017 key product net sales performance

    2017 FY results 35 2017 key product net sales performance Numbers may not add due to rounding CER: constant exchange rate

  36. Slide 36: Strong Cash Flows

    Slide 36: Strong Cash Flows

    2017 FY results 36 Strong Cash Flows "Net debt/rEBITDA ratio of 1:1" achieved ahead of time in 2016 Kremers nitrates, Urban venlafaxine ER divestiture divestiture 896 3.06* 726 537 2.13* 267 204 € million 2013 2014 2015 2016 2017 Cash flow from continuing operations Net debt & recurring EBITDA ratio

  37. Slide 37: Strong Cimzia performance across all regions

    Slide 37: Strong Cimzia performance across all regions

    2017 FY results 37 Strong Cimzia® performance across all regions Net sales1 € million FY 2017 FY 2016 Act CER For patients living with U.S. 918 846 8% 11% • Rheumatoid arthritis • Psoriatic arthritis Europe 370 339 9% 10% • Ankylosing spondylitis / International markets 136 118 15% 18% axial spondyl

  38. Slide 38: Cimzia in-market performance 2017

    Slide 38: Cimzia in-market performance 2017

    2017 FY results 38 Cimzia® in-market performance 2017 U.S. Europe Japan Cimzia® vs. Rheumatology Cimzia® vs. Rheumatology Cimzia® vs. RA Market 7% Market Growth 1 5.5% +5.4% 15% Market Growth 1 20% Growth 1 17.0% 5% 10.0% 15% 3% 10% 1.6% 7.1% 7.6% +10.6% 1% 0.1% 10% 8.0% 5% 6.4% -1% Anti TNF Biologi

  39. Slide 39: Vimpat

    Slide 39: Vimpat

    2017 FY results 39 Vimpat® Net sales1 € million FY 2017 FY 2016 Act CER For patients living with U.S. 746 629 19% 21% • Epilepsy – POS2 • Adults, adolescents and Europe 177 152 17% 17% children from 4 years of age (EU & U.S.) International markets 53 42 27% 28% • Adults (Japan) Total Vimpat® 976 822

  40. Slide 40: Vimpat in-market performance

    Slide 40: Vimpat in-market performance

    2017 FY results 40 Vimpat® in-market performance U.S. Europe Japan Vimpat® vs. AED Market Growth (TRx) Vimpat® vs. AED Market Growth (TDx) Vimpat® vs. AED Market Growth (TDx) 20% 20% 20% 16.7% 15% 15% 15% +8.2% Numbers to be 10% 8.9% 10% 10% populated when +15.1% 5.5% sufficient data is 5% 5% 5% ava

  41. Slide 41: Keppra

    Slide 41: Keppra

    2017 FY results 41 Keppra® Net sales1 € million FY 2017 FY 2016* Act CER For patients living with U.S. 232 216 7% 9% • Epilepsy – POS2 • Epilepsy – PGTCS3 Europe 235 237 -1% -1% • Epilepsy myoclonic International markets 311 267 17% 22% seizures Total Keppra® 778 720 8% 11% 2020 • Patent expiry (Jap

  42. Slide 42: Keppra in-market performance

    Slide 42: Keppra in-market performance

    2017 FY results 42 Keppra® in-market performance U.S. Europe Japan Keppra® vs. AED Market Growth (TRx) Keppra® vs. AED Market Growth Keppra® vs. AED Market Growth 5.0% 5.0% (TDx) 50% (TDx) 0.7% 4.0% 40% 0.0% 31.6% AED Market Keppra® 3.0% +0.4% 30% 2.0% -5.0% -13.7% 2.0% 20% +26.1% 1.0% 1.6% 10% 5.5%

  43. Slide 43: Briviact

    Slide 43: Briviact

    2017 FY results 43 Briviact® Net sales1 € million FY 2017 FY 2016* Act CER For patients living with U.S. 63 11 > 100% > 100% • Epilepsy – POS2 Europe 22 7 > 100% > 100% International markets 1 0 N/A N/A ® Total Briviact 87 18 >100% >100% 2020 2026 • Epilepsy POS2 • Patent expiry Phase 3 results (Jap

  44. Slide 44: Briviact in-market performance

    Slide 44: Briviact in-market performance

    2017 FY results 44 Briviact® in-market performance A new therapeutic option in the AED market U.S. Europe Briviact® – R3M TDx Share Briviact® – R3M TRx Share 0.70% 0.70% 0.58% 0.60% 0.60% 0.50% 0.50% 0.40% 0.40% 0.25% 0.30% 0.30% 0.20% 0.20% 0.10% 0.10% 0.00% 0.00% Dec-16 Mar-17 Jun-17 Sep-17 Dec-17

  45. Slide 45: Neupro

    Slide 45: Neupro

    2017 FY results 45 Neupro® Net sales1 € million FY 2017 FY 2016* Act CER For patients living with U.S. 96 85 13% 15% • Parkinson’s disease Europe 168 161 4% 5% • Restless legs syndrome International markets 50 52 -4% 0% Total Neupro® 314 298 5% 7% 2020 2021 2024 • Net sales to reach • Patent expiry

  46. Slide 46: Neupro in-market performance

    Slide 46: Neupro in-market performance

    2017 FY results 46 Neupro® in-market performance U.S. Europe Japan Neupro® PD vs. PD (KC) Neupro® PD vs. PD (KC) Neupro® PD vs. PD (KC) 9.8% 10.0% Market Growth (TRx) 10.0% Market Growth (TDx) 10% Market Growth (TDx) 8.0% 8.0% +4.4% 8% 6.0% 6.0% 5.2% 6% 4.0% 4.0% 4% 2.0% -0.8% 2.0% 0.9% 0.8% 2% +12.

  47. Slide 47: Translating scientific hypotheses into clinical development

    Slide 47: Translating scientific hypotheses into clinical development

    2017 FY results 47 Translating scientific hypotheses into clinical development Phase 1 Phase 2 Phase 3 Filing Evenity™ (romosozumab) osteoporosis bimekizumab (IL17A/F) Phase 3 program results Q4 2019 psoriasis psoriatic arthritis Phase 3 to start H2 2018 ankylosing spondylitis Phase 3 to start H2 20

  48. Slide 48: Evenity (romosozumab)

    Slide 48: Evenity (romosozumab)

    2017 FY results 48 Evenity™ (romosozumab) An innovative investigational bone-forming therapy Dual effect on bone - increases bone formation and decreases bone resorption Opportunity to build new bone and slow bone loss in osteoporosis patients at imminent risk of fragility fractures Manorama, STRUCT

  49. Slide 49: R&D milestones in 2017

    Slide 49: R&D milestones in 2017

    2017 FY results 49 R&D milestones in 2017 Vimpat® Vimpat® bimekizumab Cimzia® Cimzia® bimekizumab epilepsy POS – psoriasis epilepsy POS – ankylosing psoriasis CRIB & CRADLE ped. adj. therapy Phase 2b results pediatric spondylitis Phase 3 results filing (U.S.) Filing (U.S.) Approval (EU) Phase 2b res

  50. Slide 50: Upcoming R&D milestones

    Slide 50: Upcoming R&D milestones

    2017 FY results 50 Upcoming R&D milestones 2018 2019 2020 Cimzia® Cimzia® Vimpat® padsevonil bimekizumab seletalisib CRIB & CRADLE psoriasis epilepsy PGTCS – high drug resistant psoriatic athritis Sjögren’s syndrome label extension regulatory feedback adj. therapy epilepsy Phase 3 start Phase 2a res

  51. Slide 51: One UCB today: A global player

    Slide 51: One UCB today: A global player

    2017 FY results 51 One UCB today: A global player Presence in 38 countries complemented by a robust network of partners 7 478 employees globally December 2017

  52. Slide 52: Stable shareholder base with free-float of 62%

    Slide 52: Stable shareholder base with free-float of 62%

    2017 FY results 52 Stable shareholder base with free-float of 62% Weighted average shares outstanding in 2017: 188 million “Free float” investors by region Source: Notifications and UCB underlying ownership analysis, Dec. 2017

  53. Slide 53: Your UCB Investor Relations team

    Slide 53: Your UCB Investor Relations team

    2017 FY results 53 Your UCB Investor Relations team ‫ ן‬Antje Witte, Vice President Investor Relations • Phone: +32 2 559 9414 • E-mail: antje.witte@ucb.com ‫ ן‬Isabelle Ghellynck, Director Investor Relations • Phone: +32 2 559 9588 • E-mail: isabelle.ghellynck@ucb.com ‫ ן‬Nathalie Deldime, Investor

Source: Internet Archive copy of ucb.com

More decks from Ucb S.A.

All 41 Ucb decks